Ozempic现在获得批准,以帮助预防糖尿病患者的肾病和心脏病死亡。 Ozempic now approved to help prevent kidney disease and heart deaths in diabetes patients.

林业发展局批准了Ozempic,一种治疗2型糖尿病的药物,以降低两种病症患者患慢性肾病恶化、肾衰竭和心脏病死亡的风险。 The FDA has approved Ozempic, a medication for type 2 diabetes, to also reduce risks of chronic kidney disease worsening, kidney failure, and heart-related death in patients with both conditions. 临床试验显示,Ozempic将肾病发作的风险降低了24%,将心脏病死亡人数减少了5%左右。 Clinical trials showed that Ozempic reduced the risk of kidney disease progression by 24% and cut heart disease deaths by about 5%. 这一批准扩大了Ozempic的使用范围,使其成为该类药物中最广泛标明的药物。 This approval expands Ozempic's use, making it the most broadly indicated drug in its class.